Core Viewpoint - Henan Lingrui Pharmaceutical Co., Ltd. has established itself as a household name in the pain relief patch market through innovative production techniques and product development. Group 1: Production Innovations - The company utilizes smart manufacturing technologies, including self-developed digital extraction equipment, to enhance the efficiency, environmental sustainability, and energy conservation of traditional Chinese medicine extraction [2][3]. - A centralized control center monitors over 300 production data points in real-time, ensuring quality stability across different batches of herbal extracts [3]. - The integration of an intelligent logistics and warehousing system has created a "digital highway" from production to shipping, incorporating advanced technologies such as AGV systems and drug traceability [3]. Group 2: Product Development - Lingrui Pharmaceutical has expanded its product line beyond traditional patches, introducing innovative products like the indomethacin patch, which employs advanced laser micropore technology for enhanced functionality [4]. - The company is actively developing new products, including a novel nasal spray for treating cold symptoms, which is expected to broaden its therapeutic applications and clinical value [5]. - The annual sales of the "Two Tigers" patch series have exceeded 1 billion patches, covering various medical fields such as orthopedics, neurology, respiratory medicine, anesthesiology, dermatology, and pediatrics [5]. Group 3: Investment in R&D - Lingrui Pharmaceutical commits 3% to 5% of its annual revenue to research and development, establishing high-level platforms such as a national enterprise technology center and a postdoctoral research workstation [5]. - The company's approach demonstrates that the heritage of traditional brands can serve as a foundation for innovation, enabling them to navigate market cycles and achieve high-quality growth [5].

Core Insights - The company, Lingrui Pharmaceutical, has established itself as a household name in the production of medicated plasters, leveraging advanced technology and innovation to enhance product quality and production efficiency [1][2][3] Group 1: Production and Technology - Lingrui Pharmaceutical has implemented smart manufacturing systems, including a digital extraction process that ensures the quality stability of traditional Chinese medicine extracts [1] - The company has developed an integrated ERP data platform that connects sales, production, and inventory data, allowing for real-time intelligent production scheduling and energy-efficient operations [2] - The production facility is capable of producing 10,000 medicated plasters per minute, showcasing the efficiency of its smart manufacturing processes [1] Group 2: Product Development and Market Position - The company has expanded its product line through continuous research and development, with its "Two Tigers" medicated plaster series achieving annual sales exceeding 1 billion plasters [3] - Lingrui Pharmaceutical is set to launch a new innovative drug, a nasal spray for treating cold symptoms, which will broaden its therapeutic offerings and enhance clinical value [3] - The company invests 3% to 5% of its annual revenue into research and development, establishing high-level platforms such as a national enterprise technology center and a postdoctoral research workstation [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in terms of profit is outstanding, with a revenue of 3.501 billion yuan in 2024 (up 5.72% year-on-year) and a net profit attributable to shareholders of 722.55 million yuan (up 27.19% year-on-year) [2] - In Q1 2025, the company achieved a revenue of 1.021 billion yuan (up 12.29% year-on-year, up 37.62% quarter-on-quarter) and a net profit of 217 million yuan (up 13.89% year-on-year, up 45.83% quarter-on-quarter) [2] - The company is a leading player in the traditional Chinese medicine patch market, with a strong performance in core products and a promising growth outlook due to recent acquisitions [6][7] Summary by Sections Financial Performance - In 2024, the company reported a gross margin of 75.82% and a net margin of 20.64%, with improvements in gross margins across various product lines [6] - The company plans to enhance its product pipeline through the acquisition of Yingu Pharmaceutical for 704 million yuan, which is expected to provide significant synergies and fill gaps in its product offerings [6][7] Revenue Breakdown - The revenue from patches reached 2.115 billion yuan in 2024 (up 3.35% year-on-year), while tablets saw a significant increase of 35.60% year-on-year, reaching 355 million yuan [6] - The core product Tongluo Qutong Gao is expected to generate over 1.2 billion yuan in revenue, with double-digit growth anticipated for the "Two Tigers" series [6] Earnings Forecast - The company is expected to achieve net profits of 826.30 million yuan, 951.24 million yuan, and 1.07982 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.46, 1.68, and 1.90 yuan [7]

涉及总金额4 0 8 . 5 3亿元人民币。 作者 | 私募通 来源 | 决策投资圈 （ID：PEDATAMAX） 清科创业（0 1 9 4 5 .HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购共 1 4 8起事件，涉及总金额4 0 8.53亿人民币。从交易金额来看，本周金额较大事件是： 2 0 25年3月4日，全国社会保障基金理事会投资国投电力控股股份有限公司7 0 . 0 0亿人民 币。从交易事件地域分布看，目前主要分布在上海市、北京市和江苏省，占比为上海市 2 0 .5%，北京市1 6 . 7%，江苏省14.1%。 01 本周募资情况 本周新登记股权投资基金管理人共计0家，取消备案登记4家，全年截至目前累计股权投 资基金管理人数量为11家。本周新增备案基金数量为70只，规模总计1 4 6 . 5 1亿元，本周 备案基金募资最多的为合肥市包河区产发创业投资合伙企业（有限合伙）和绵阳涪江新 兴股权投资合伙企业（有限合伙），募集20.00亿人民币。全年截至目前累计股权投资备 案基金数量为7 0 1只，规模总计5705.25亿元。（2025年2月2 8日- 2 0 2 5年3月6日） 投资金额TO ...